115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation
    Meeting Abstract

    Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
    Meeting Abstract

    Shastri, A.; Feldman, E. J.; Starodub, A. N.; Feldman, T.; Rodriguez, C. P.; Epstein-Peterson, Z. D.; Stevens, D. A.; Olszewski, A. J.; Huen, A. O.; Porcu, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PROMMIS trial prospectively demonstrates the efficacy of SKY92 risk stratification in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; McKay, J. T.; Vesole, D. H.; Nooka, A. K.; Paul, B.; Hari, P. N.; Stork-Sloots, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - A US multisite study
    Meeting Abstract

    Epperla, N.; Annunzio, K.; Shouse, G. P.; Grover, N. S.; Torka, P.; Watkins, M. P.; Anampa-Guzmán, A. C.; Oh, T. S.; Reves, H.; Tavakkoli, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) among patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving pirtobrutinib: Analysis from the BRUIN phase 1/2 study
    Meeting Abstract

    Coombs, C. C.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Tam, C. S.; Seymour, J. F.; Shah, N. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pts) with R/R MCL: Subgroup analyses in pts with high-risk disease features from the MCL cohort of the TRANSCEND NHL 001
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J. E.; Ghosh, N.; Mehta, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma treated with venetoclax: A multicenter retrospective analysis
    Meeting Abstract

    Sawalha, Y.; Sarosiek, S. R.; Welkie, R. L.; Seif, S.; Thapa, S.; Zanwar, S.; Cahill, K.; Treitman, R.; Shah, H.; Arora, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative analysis of clinical outcomes and healthcare resource utilization (HRU) in patients (pts) with newly diagnosed (nd) acute myeloid leukemia (aml) unfit for high-intensity chemotherapy treated with venetoclax (VEN) vs other therapies: Results from the AML real world evidence (ARC) initiative
    Meeting Abstract

    Desai, P.; Garcia, J. S.; Zeidner, J. F.; Abedin, S.; Wolach, O.; Vachhani, P.; Moshe, Y.; Pollyea, D. A.; Lai, C.; LeBlanc, T. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Safety and tolerability of Magrolimab combinations in patients with relapsed/refractory multiple myeloma (RRMM): Safety run-in results from a phase 2 Study
    Meeting Abstract

    Paul, B.; Minarík, J.; Cottini, F.; Gasparetto, C.; Khouri, J.; Gandhi, M.; Hillengass, J.; Levy, M.; Liedtke, M.; Manda, S.; more...
    Blood (2023)

    Fulltext@MSK | Save